Intercytex Limited

Development of a new generation of cell-based therapies for the treatment of tissue and organ failure, especially for chronic wounds and hair transplantation

Intercytex started business in 2000 as a regenerative medicine company and has 50 employees including R&D, clinical production and regulatory teams. Its main labs and offices are situated in Manchester, UK; a further research facility is located in Boston, Massachusetts. Till today the company has raised over £31 million in four private equity funding rounds. In August the company raised £12 million in a private equity financing from its existing shareholders.

Nick Higgins, CEO, Executive Director
Richard Moulson, CFO, Executive Director
Paul Kemp, Ph.D., Founder,CSO and Executive Director
John St Clair Roberts, VP Clinical & Regulatory Affairs
Jan Benschop, VP - Commercial Development
John Lovelady, Ph.D., VP - Operations

Ian Kent, Chairman
Alan Suggett, Ph.D.
John Aston
Nick Higgins
Paul Kemp
Richard Moulson

St John’s Innovation Centre
Cowley Road
Cambridge
CB4 0WS
UK
Phone: +44-(0)161-904-4500
Fax: +44-(0)1223-421961

Intercytex is focused on cell-based therapies. One major product (ICX-PRO) is designed to stimulate repair in chronic dermal wounds. It consists of two components: a diffuse population of allogeneic virally-validated fibroblasts and a fibrin-based matrix delivery system. Principal indications for this product are venous stasis and diabetic ulcers.

The second product of the company is a next generation of hair transplants to treat hair loss, which combines the culture and expansion of follicular cells which are injected into the scalp underneath the epidermis of the skin to induce formation of new hair follicles in-situ (ICX-TRC).

A third product, ICX-SKN, is developed as a true skin replacement.

Intercytex has two products (hair transplants, wound healing) currently in clinical development, ICX-PRO and ICX-TRC. ICX-PRO has entered a multi-centre Phase III clinical trial in 2005. Results of the Phase III study that involves 200 patients are expected by the end of 2006. ICX-TRC is tested in Phase I trials.

The following section contains a selection of the company’s most relevant patents. For comprehensive patent information please refer to the espacenet databases.